Jul 24, 2025 8:00am EDT Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology
Jul 08, 2025 8:30am EDT Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Jul 07, 2025 7:00am EDT Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
Jun 30, 2025 7:05am EDT Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
Jun 10, 2025 6:00am EDT Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
May 21, 2025 7:00am EDT Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders
May 14, 2025 7:15am EDT Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
Apr 10, 2025 8:00am EDT Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis
